Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia

[1] Siegel RL(2016)Cancer Statistics, 2016 CA Cancer J Clin 66 7-30

[2] Miller DK(2004)Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model J Surg Res 120 295-303

[3] Jemal A(2012)Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment PLoS One 7 e50165-169

[4] Büchler P(2016)Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer Pharmacol Ther 164 152-316

[5] Reber HA(2016)The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol 10 301-2607

[6] Lavey RS(2007)The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling Ann Surg Oncol 14 2600-1454

[7] Tomlinson J(2007)Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 1441-980

[8] Büchler MW(2007)Pretreatment J Nucl Med 48 973-947

[9] Friess H(2010)F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine Acta Oncol 49 941-922

[10] Hines OJ(2000)Evaluating repetitive 18 F-fluoroazomycin-arabinoside ( Int J Radiat Oncol Biol Phys 48 919-3120

[1] Siegel RL(2016)Cancer Statistics, 2016 CA Cancer J Clin 66 7-30

[2] Miller DK(2004)Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model J Surg Res 120 295-303

[3] Jemal A(2012)Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment PLoS One 7 e50165-169

[4] Büchler P(2016)Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer Pharmacol Ther 164 152-316

[5] Reber HA(2016)The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol 10 301-2607

[6] Lavey RS(2007)The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling Ann Surg Oncol 14 2600-1454

[7] Tomlinson J(2007)Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 1441-980

[8] Büchler MW(2007)Pretreatment J Nucl Med 48 973-947

[9] Friess H(2010)F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine Acta Oncol 49 941-922

[10] Hines OJ(2000)Evaluating repetitive 18 F-fluoroazomycin-arabinoside ( Int J Radiat Oncol Biol Phys 48 919-3120